Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection

OBJECTIVES: Ridinilazole (SMT19969) is a narrow-spectrum, non-absorbable antimicrobial with activity against Clostridium difficile undergoing clinical trials. The purpose of this study was to assess the pharmacological activity of ridinilazole and assess the effects on cell morphology. METHODS: Anti...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Antimicrob Chemother
Autori principali: Bassères, Eugénie, Endres, Bradley T., Khaleduzzaman, Mohammed, Miraftabi, Faranak, Alam, M. Jahangir, Vickers, Richard J., Garey, Kevin W.
Natura: Artigo
Lingua:Inglês
Pubblicazione: Oxford University Press 2016
Soggetti:
Original Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4830417/
https://ncbi.nlm.nih.gov/pubmed/26895772
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkv498
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi